Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 14/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943875 | 0.82 | S1PR1 (0.44) | MAPTFAAH | |
| SCHEMBL2944777 | 0.82 | S1PR1 (0.44) | MAPTFAAH | |
| SCHEMBL2942289 | 0.81 | TP53 (0.36) | MAPTKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL2943798 | 0.80 | ALDH1A1 (0.50) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL3257824 | 0.72 | DGAT1 (0.45) | MAPTGAAFAAHL3MBTL1 | |
| SCHEMBL3252126 | 0.69 | OXTR (0.43) | MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL13175642 | 0.69 | MAPT (0.52) | MAPTALDH1A1 | |
| SCHEMBL3258126 | 0.67 | NAMPT (0.46) | MAPTHPGDGAAFAAHL3MBTL1 | |
| SCHEMBL4407217 | 0.66 | HSP90AA1 (0.65) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL10769451 | 0.66 | PTGES (0.58) | MAPTKDM4EALDH1A1GAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | claimed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | claimed |
| JP-2007517887-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1709047-A2 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-10-11 | — | — | EP | claimed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | claimed |
| WO-2005067900-A2 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | NAT1, PIGS, ADORA1 | MAPT 4359/4885KDM4E 626/4885ALDH1A1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.